Study guide

9.6 Surfactant Administration & Response

NBRC RRT-NPS Neonatal/Pediatric Specialist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neonatal and Pediatric Patient Assessment

1.1 Maternal, Obstetric & Perinatal History 1.2 Fetal Surveillance & Antepartum Diagnostics 1.3 Gestational Age & Baseline Neonatal Examination 1.4 Apgar, Respiratory Distress & Thoracic Assessment 1.5 Pediatric Assessment Triangle & Vital Signs 1.6 Neurologic Assessment, Respiratory Failure & Triage

2 Chapter 2: Diagnostic Evaluation & Gas Exchange Monitoring

2.1 Pulse Oximetry, Pre/Postductal & Transcutaneous Monitoring 2.2 Capnography, Waveforms & Dead-Space Evaluation 2.3 Arterial & Capillary Blood-Gas Sampling 2.4 Umbilical Lines, Acid-Base & Laboratory Evaluation 2.5 Chest Imaging & Airway Radiography 2.6 Pulmonary Function, Bronchoscopy & Specimen Diagnostics

3 Chapter 3: Airway Management & Secretion Clearance

3.1 Pediatric Airway Anatomy & ETT Sizing 3.2 Cuffed Airways, Intubation & Difficult-Airway Management 3.3 Tracheostomy Devices & Routine Care 3.4 Tracheostomy Emergencies, Speaking & Decannulation 3.5 Airway Suctioning Technique & Safety 3.6 Airway Clearance, Home Care & Discharge Planning

4 Chapter 4: Pharmacology & Medical Gas Therapy

4.1 Aerosol Physics & Delivery Devices 4.2 Respiratory & Systemic Pharmacology 4.3 Oxygen Interfaces & Delivery Systems 4.4 Oxygen Blenders, Targets & Toxicity 4.5 HFNC Physiology, Sizing & Flow 4.6 HFNC Indications, Monitoring & Escalation

5 Chapter 5: Shared Neonatal & Pediatric Pulmonary Disorders

5.1 Neonatal RDS Pathophysiology & Management 5.2 TTN, Pneumonia & the Neonatal Differential 5.3 Meconium Aspiration & PPHN 5.4 BPD, Apnea & Chronic Neonatal Lung Disease 5.5 Bronchiolitis, Croup & Epiglottitis 5.6 Asthma, Cystic Fibrosis & Foreign-Body Aspiration

6 Chapter 6: Resuscitation, Emergency Protocols & Patient Safety

6.1 NRP Cord Management, Initial Steps & Ventilation 6.2 NRP Corrective Steps, Compressions & Medications 6.3 PALS Assessment, CPR & Cardiac Arrest 6.4 PALS Dysrhythmia & Shock Management 6.5 Neonatal & Pediatric Transport 6.6 Patient Safety, Teamwork & Family-Centered Care

7 Chapter 7: Noninvasive & Conventional Mechanical Ventilation

7.1 Bubble CPAP & Neonatal NIV 7.2 Pediatric NIV, Interfaces & Failure Recognition 7.3 Conventional Ventilation Physics & Modes 7.4 Initial Settings & ABG-Guided Titration 7.5 Ventilator Scalars & Loops 7.6 Ventilator Dyssynchrony & Troubleshooting 7.7 Weaning Readiness & Spontaneous Breathing Trials 7.8 Extubation & Post-Extubation Airway Risk

8 Chapter 8: High-Frequency Ventilation & Advanced Modes

8.1 HFOV Mechanics & Gas Transport 8.2 HFOV Controls & Clinical Management 8.3 HFJV Circuit & Controls 8.4 HFJV Servo Pressure & Clinical Indications 8.5 NAVA, Edi & Proportional Support 8.6 APRV in Pediatric Respiratory Failure

9 Chapter 9: Specialty Inhaled Gases & Exogenous Surfactant Therapy

9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose 9.2 Inhaled Nitric Oxide: Toxicity, Monitoring & Weaning 9.3 Heliox Physics & Delivery 9.4 Volatile Anesthetic & Subambient Gas Therapy 9.5 Surfactant Biology, Products & Dosing 9.6 Surfactant Administration & Response

10 Chapter 10: Pediatric ARDS & Parenchymal Critical Illness

10.1 PALICC-2 Diagnosis & Severity 10.2 PALICC-2 NIV & Possible PARDS 10.3 PARDS Lung-Protective Ventilation 10.4 PARDS Refractory Hypoxemia & Adjuncts 10.5 PIE & Pneumothorax Recognition 10.6 Thoracic Decompression & Chest Drains

11 Chapter 11: Congenital Heart Disease & Hemodynamic Management

11.1 Left-to-Right Shunts & Qp/Qs Physiology 11.2 Acyanotic Lesions & Respiratory Management 11.3 Cyanotic Lesions & the Five Ts 11.4 Ductal Dependence, PGE1 & the Hyperoxia Test 11.5 Single-Ventricle Physiology & Staged Palliation 11.6 Gas Balancing, Hemodynamics & NIRS

12 Chapter 12: Advanced Critical Care: ECMO, Neurotrauma & Palliative Care

12.1 ECMO Candidacy & Modality 12.2 ECMO Circuit, Lung Rest & Anticoagulation 12.3 Neurotrauma, ICP & Ventilation 12.4 Neonatal Therapeutic Hypothermia & Respiratory Care 12.5 Death by Neurologic Criteria: Examination & Apnea Testing 12.6 DNC Timing, Ancillary Testing, Palliation & Donation

9.6 Surfactant Administration & Response

Key Takeaways Explain This Topic AI

Delivery options include endotracheal instillation, INSURE, and less-invasive surfactant administration (LISA/MIST). For selected spontaneously breathing preterm infants on CPAP, LISA can reduce exposure to invasive ventilation but does not guarantee avoidance of intubation or rescue ventilation.

After surfactant, improving compliance and oxygenation can rapidly increase tidal volume and saturation. Reassess continuously and titrate pressure or volume and FiO2 to the infant’s response. Avoid routine suctioning for the product- and protocol-specified interval unless airway obstruction requires intervention.

Poractant alfa is dosed at 200 mg/kg (2.5 mL/kg) initially and 100 mg/kg (1.25 mL/kg) for repeat doses, so an 800 g infant receives 160 mg in 2.0 mL.

Over-ventilation after surfactant can drive PaCO2 below 25 to 30 mmHg and cause cerebral vasoconstriction and periventricular leukomalacia; pulmonary hemorrhage risk is highest in extremely low-birth-weight infants with a large patent ductus arteriosus.

Last updated: September 2026

  • 9.6 Surfactant Administration & Response
  • Surfactant Administration Modalities SURFACTANT DELIVERY STRATEGIES
  • TRADITIONAL ETT INSTILLATION LISA / MIST METHOD
  • ┌──────────────────────────────┐ ┌──────────────────────────────┐
  • │ Intubated neonate │ │ Spontaneously breathing │
  • │ Positive pressure vent │ │ Noninvasive Bubble CPAP │
  • │ Instilled via multi-access │ │ Thin vascular catheter / tube│
  • │ catheter or dual-lumen ETT │ │ passed through vocal cords │
  • │ Administered in 2–4 aliquots │ │ Surfactant instilled over │
  • │ with position changes │ │ 1–3 min; catheter removed │
  • └──────────────┬───────────────┘ └──────────────┬───────────────┘
  • │ │
  • ▼ ▼
  • INSURE (INtubate-SURfactant-Extubate) AVOIDS MECHANICAL VENTILATION
  • Intubate ──► Dose ──► Extubate to CPAP • Limits planned ETT ventilation
  • Target extubation within 30–60 min • Reduces BPD & pneumothorax
  • 1. Traditional Endotracheal Instillation via Side-Port / Multi-Access Catheter

The infant is intubated with an endotracheal tube.

A dedicated multi-access closed suction catheter or side-port delivery adapter is attached.

The calculated dose is drawn into a syringe and instilled directly into the trachea in 2 to 4 aliquots .

Historically, the infant was rotated into right and left lateral decubitus positions between aliquots to facilitate gravity-assisted lobar distribution. Modern practice recognizes that rapid fluid capillary action distributes surfactant effectively without requiring extreme patient repositioning.

2. The INSURE Technique (INtubate - SURfactant - Extubate)

Designed to deliver surfactant while avoiding prolonged mechanical ventilation.

Preterm infants demonstrating moderate-to-severe RDS on CPAP are electively intubated, administered surfactant via ETT, briefly ventilated to ensure alveolar dispersion, and extubated directly back to nasal CPAP within 30 to 60 minutes 30\text{ to }60\text{ minutes} 30 to 60 minutes .

3. Less Invasive Surfactant Administration (LISA) / Minimally Invasive Surfactant Therapy (MIST)

A preferred option for selected infants: Many neonatal guidelines favor LISA/MIST for spontaneously breathing preterm infants on CPAP when the team has suitable expertise; eligibility and technique remain protocol-dependent.

Technique:

The preterm infant remains spontaneously breathing on continuous noninvasive positive airway pressure (typically Bubble CPAP at 6 to 8 cmH 2 O 6\text{ to }8\text{ cmH}_2\text{O} 6 to 8 cmH 2 ​ O ).

Under direct laryngoscopy or video laryngoscopy, a thin, flexible small-bore catheter (e.g., a 16–18 gauge Angiocath or a 4–5 Fr feeding tube) is gently advanced through the vocal cords into the upper trachea.

Surfactant (preferably high-concentration Poractant alfa due to its low volume) is slowly instilled into the trachea over 1 to 3 minutes 1\text{ to }3\text{ minutes} 1 to 3 minutes while the infant continues spontaneous breathing.

The spontaneous negative inspiratory thoracic pressure draws the surfactant droplets down into the bronchial tree, while CPAP preserves functional residual capacity.

The catheter is removed immediately upon completion of instillation.

Clinical Benefits and limits: LISA can reduce exposure to endotracheal positive-pressure ventilation and may reduce mechanical-ventilation-related complications in appropriate infants. It still requires laryngoscopy and tracheal catheterization, and apnea, treatment failure, or deterioration may require rescue ventilation or intubation.

Acute Physiological Responses, Hazards & Ventilator Management

Administering exogenous surfactant triggers immediate, profound biomechanical changes within the neonatal lung. The respiratory therapist must anticipate these changes and intervene instantly at the bedside. ACUTE POST-SURFACTANT PHYSIOLOGICAL CASCADE

  • [SURFACTANT INSTILLATION]
  • │
  • Surfactant Spreads Rapidly & Lowers
  • Alveolar Surface Tension
  • │
  • ▼
  • RAPID IMPROVEMENT IN COMPLIANCE & OXYGENATION
  • (Magnitude and timing vary by infant)
  • │
  • ┌─────────────────────────┴─────────────────────────┐
  • ▼ ▼
  • IF VENTILATOR SETTINGS IF VENTILATOR SETTINGS
  • REMAIN UNCHANGED ARE PROMPTLY REDUCED
  • │ │
  • Massive Tidal Volume Spikes • PIP titrated down rapidly
  • (VT jumps 4 mL/kg ──► 12 mL/kg) • Target VT (4–6 mL/kg) preserved
  • Severe Alveolar Overdistension • FiO2 rapidly weaned
  • PULMONARY INTERSTITIAL EMPHYSEMA (PIE) • Normocarbia maintained
  • TENSION PNEUMOTHORAX • SAFE LUNG RECOVERY
  • SEVERE HYPOCARBIA (PaCO2 < 25 mmHg)
  • (Triggers Cerebral Vasoconstriction & PVL)
  • 1. Immediate Reassessment and Ventilator Actions

Ventilator reassessment: Compliance and oxygenation may improve rapidly, so the same pressure can produce a larger tidal volume. Continuously monitor exhaled volume and chest movement and reduce pressure promptly when indicated; do not make an automatic fixed reduction before observing the response.

FiO2 titration: Oxygenation may improve quickly. Reduce FiO2 promptly as indicated to remain within the infant’s prescribed gestation- and condition-specific saturation range and avoid hyperoxemia.

Prevention of Hypocarbia: Over-ventilation plunges P a C O 2 PaCO_2 P a C O 2 ​ rapidly below 25 to 30 mmHg 25\text{ to }30\text{ mmHg} 25 to 30 mmHg . Severe hypocarbia causes profound cerebral arteriolar vasoconstriction, resulting in cerebral ischemia and Periventricular Leukomalacia (PVL) .

2. Peri-Administration Complications & Interventions

Transient Airway Obstruction & Desaturation: Instilling a fluid bolus into a 2.5 or 3.0 mm 2.5\text{ or }3.0\text{ mm} 2.5 or 3.0 mm ETT creates a liquid meniscus that transiently obstructs gas flow, causing acute cyanosis and vagal bradycardia.

Action: Immediately pause instillation. Increase ventilator PIP by 2 to 3 cmH 2 O 2\text{ to }3\text{ cmH}_2\text{O} 2 to 3 cmH 2 ​ O and transiently increase F i O 2 FiO_2 F i O 2 ​ until the heart rate recovers ( > 100 bpm > 100\text{ bpm} > 100 bpm ) and saturations stabilize. Once cleared, resume instillation at a slower pace.

Post-dose suctioning:

Avoid routine endotracheal suctioning during the interval specified by the surfactant manufacturer and local protocol; for some products this is about 1 hour.

If ventilation is impaired by suspected tube obstruction, assess patency and intervene without delaying necessary airway care.

Pulmonary Hemorrhage Risk: A recognized complication of surfactant therapy occurring primarily in extremely low-birth-weight (ELBW, < 1000 g < 1000\text{ g} < 1000 g ) infants with a large patent ductus arteriosus (PDA). As PVR falls rapidly post-surfactant, left-to-right ductal shunting surges, flooding the pulmonary capillaries and causing capillary stress failure. This requires immediate neonatal critical-care escalation: stabilize the airway and gas exchange, titrate PEEP and oxygen to the infant’s response, correct hemodynamic or coagulation problems, and individualize any repeat surfactant decision.

  • Worked Clinical Calculation: Surfactant Dosing Formulation
  • Clinical Scenario

A 27-week gestational age female infant weighing 800 grams 800\text{ grams} 800 grams ( 0.80 kg 0.80\text{ kg} 0.80 kg ) is delivered via urgent cesarean section for maternal pre-eclampsia. The infant develops severe respiratory distress syndrome requiring endotracheal intubation. The physician orders Poractant alfa (Curosurf) for the initial therapeutic dose.

Step-by-Step Dosing Calculation

Determine Initial Weight-Based Dose:

Recommended initial dose of Poractant alfa = 200 mg/kg = \mathbf{200\text{ mg/kg}} = 200 mg/kg ( 2.5 mL/kg 2.5\text{ mL/kg} 2.5 mL/kg ).

Calculate Total Dose in Milligrams (mg): Total Dose (mg) = 0.80 kg × 200 mg/kg = 160 mg \text{Total Dose (mg)} = 0.80\text{ kg} \times 200\text{ mg/kg} = \mathbf{160\text{ mg}} Total Dose (mg) = 0.80 kg × 200 mg/kg = 160 mg

Calculate Total Volume to Administer in Milliliters (mL):

Poractant alfa concentration = 80 mg/mL = 80\text{ mg/mL} = 80 mg/mL . Total Volume (mL) = 160 mg 80 mg/mL = 2.0 mL \text{Total Volume (mL)} = \frac{160\text{ mg}}{80\text{ mg/mL}} = \mathbf{2.0\text{ mL}} Total Volume (mL) = 80 mg/mL 160 mg ​ = 2.0 mL

(Cross-check via volume multiplier: 0.80 kg × 2.5 mL/kg = 2.0 mL 0.80\text{ kg} \times 2.5\text{ mL/kg} = 2.0\text{ mL} 0.80 kg × 2.5 mL/kg = 2.0 mL ) .

Calculate Subsequent Repeat Doses (if required at 12 hours):

Repeat dose = 100 mg/kg = 100\text{ mg/kg} = 100 mg/kg ( 1.25 mL/kg 1.25\text{ mL/kg} 1.25 mL/kg ). Repeat Dose (mg) = 0.80 kg × 100 mg/kg = 80 mg \text{Repeat Dose (mg)} = 0.80\text{ kg} \times 100\text{ mg/kg} = \mathbf{80\text{ mg}} Repeat Dose (mg) = 0.80 kg × 100 mg/kg = 80 mg Repeat Volume (mL) = 0.80 kg × 1.25 mL/kg = 1.0 mL \text{Repeat Volume (mL)} = 0.80\text{ kg} \times 1.25\text{ mL/kg} = \mathbf{1.0\text{ mL}} Repeat Volume (mL) = 0.80 kg × 1.25 mL/kg = 1.0 mL

Therapist Execution: The therapist warms a vial of Curosurf to room temperature, gently inverts it, draws up precisely 2.0 mL 2.0\text{ mL} 2.0 mL into a sterile syringe, and delivers it via a side-port catheter while continuously monitoring heart rate, S p O 2 SpO_2 Sp O 2 ​ , and expired tidal volume.

NPS Exam Traps

Warning

Exam Trap 1: The "Post-Surfactant Pneumothorax"

After surfactant, rapidly improving compliance can make previously appropriate pressure deliver excessive tidal volume. Reassess pressure, volume, FiO2, and chest symmetry immediately. Sudden unilateral absent sounds with shock should be treated as tension pneumothorax without waiting for imaging; the teaching point is active titration to response, not an automatic fixed pressure reduction in every infant.

Exam Trap 2: Post-Surfactant Endotracheal Suctioning

Avoid routine suctioning during the product- and protocol-specified post-dose interval when ventilation is effective. Coarse sounds alone do not require suction, but suspected ETT obstruction with impaired ventilation warrants immediate patency assessment and necessary airway care.

Exam Trap 3: The Refractory Full-Term Infant

In a term infant with severe diffuse disease and little sustained response to exogenous surfactant, include inherited surfactant dysfunction such as SFTPB disease in the differential. Infection, pulmonary hypertension, structural disease, and other genetic disorders must also be evaluated. Genotype and residual protein influence phenotype, so nonresponse alone is not diagnostic and specialist genetic testing is required.